Patrick H. Nachman
A5042064091- Renal Diseases and Glomerulopathies
- Vasculitis and related conditions
- Coagulation, Bradykinin, Polyphosphates, and Angioedema
- Chronic Kidney Disease and Diabetes
- Otitis Media and Relapsing Polychondritis
- Autoimmune Bullous Skin Diseases
- Urticaria and Related Conditions
- Hemoglobinopathies and Related Disorders
- Systemic Lupus Erythematosus Research
- Neutrophil, Myeloperoxidase and Oxidative Mechanisms
- Amyloidosis: Diagnosis, Treatment, Outcomes
- Cell Adhesion Molecules Research
- Iron Metabolism and Disorders
- Heparin-Induced Thrombocytopenia and Thrombosis
- Dialysis and Renal Disease Management
- Sarcoidosis and Beryllium Toxicity Research
- Pregnancy and Medication Impact
- Renal and related cancers
- Blood disorders and treatments
- Venous Thromboembolism Diagnosis and Management
- Systemic Sclerosis and Related Diseases
- Inflammatory Bowel Disease
- Renal Transplantation Outcomes and Treatments
- Renal and Vascular Pathologies
- Bipolar Disorder and Treatment
University of Minnesota
2017-2025
University of Geneva
2025
Twin Cities Orthopedics
2021-2024
University of Minnesota Medical Center
2022-2024
University of North Carolina at Chapel Hill
2012-2023
University of Michigan
2023
Zero to Three
2023
Creative Commons
2023
Cedars-Sinai Medical Center
2023
Arkana Laboratories
2023
Predictors of treatment resistance and relapse have not been well described in antineutrophil cytoplasmic antibody (ANCA)-associated small-vessel vasculitis.To identify clinical, pathologic, serologic predictors a community-based cohort patients with ANCA-associated vasculitis.Cohort identified at or near the time biopsy diagnosis followed as clinically indicated.The Glomerular Disease Collaborative Network.350 who received new vasculitis between 1985 2003 were for median 49 months.Patients...
Abstract Objective To compare the usefulness of 3 currently used classification systems in predicting outcomes treatment resistance, disease relapse, end‐stage renal (ESRD), and death patients with antineutrophil cytoplasmic antibody (ANCA)–associated vasculitis (AAV). Methods Three were applied to 502 biopsy‐proven AAV: 1) Chapel Hill Consensus Conference (CHCC) definition categories for granulomatosis polyangiitis (GPA) (Wegener's), microscopic (MPA), kidney‐limited disease; 2) European...
The purpose of this study was to determine the prognostic value clinical, laboratory, and pathologic features at time presentation on patient renal survival in patients with antineutrophil cytoplasmic autoantibody (ANCA)-associated microscopic polyangiitis glomerulonephritis (excluding Wegener's granulomatosis). One hundred seven ANCA-positive necrotizing crescentic glomerulonephritis, including 69 evidence for polyangiitis, were evaluated study. relative risk death calculated following...
Background and objectives: It was postulated that in patients with membranous nephropathy (MN), four weekly doses of Rituximab (RTX) would result more effective B cell depletion, a higher remission rate, maintaining the same safety profile compared treated RTX dosed at 1 g every 2 weeks. This hypothesis supported by previous pharmacokinetic (PK) analysis showing levels two-dose regimen were 50% lower nonproteinuric patients, which could potentially undertreatment. Design, setting,...
Anti-neutrophil cytoplasmic antibody–associated (ANCA-associated) small vessel necrotizing vasculitis is caused by immune-mediated inflammation of the wall and diagnosed in some cases presence myeloperoxidase-specific antibodies (MPO-ANCA). This multicenter study sought to determine whether differences ANCA epitope specificity explain why, cases, conventional serologic assays do not correlate with disease activity, why naturally occurring anti-MPO autoantibodies can exist disease-free...
The Kidney Disease: Improving Global Outcomes (KDIGO) initiative organized a Controversies Conference on glomerular diseases in November 2017. conference focused the 2012 KDIGO guideline with aim of identifying new insights into nomenclature, pathogenesis, diagnostic work-up, and, particular, therapy since guideline's publication. It was consensus group that most recommendations, particular those dealing therapy, will need to be revisited by guideline-updating Work Group. This report covers...
Evaluation of rituximab and glucocorticoids as therapy to induce remission after relapse in ANCA-associated vasculitis (AAV) a prospective observational cohort patients enrolled into the induction phase RITAZAREM trial.
Objective Following induction of remission with rituximab in anti-neutrophil cytoplasmic antibody-associated vasculitis (AAV) relapse rates are high, especially patients history relapse. Relapses associated increased exposure to immunosuppressive medications, the accrual damage and morbidity mortality. The RITAZAREM trial compared efficacy repeat-dose daily oral azathioprine for prevention relapsing AAV whom was reinduced rituximab. Methods an international randomised controlled, open-label,...
In this study, the rate of remission, relapse, and treatment resistance in 107 patients with microscopic polyangiitis necrotizing crescentic glomerulonephritis associated antineutrophil cytoplasmic autoantibodies were assessed. Patients Wegener's granulomatosis excluded. Prospective criteria identified to assess resistant disease. Ninety-seven received corticosteroids (N = 25) or cyclophosphamide 72). Of these patients, 75 (77.3%) went into remission (complete N 61; on therapy, 14)....
Predictors of treatment resistance and relapse have been identified in patients with antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis the Glomerular Disease Collaborative Network (GDCN) southeastern US. This study was undertaken to evaluate applicability those predictors an independent cohort followed up by French Vasculitis Study Group.Predictors were evaluated using logistic regression models reported as odds ratios (ORs) 95% confidence intervals (95% CIs). Cox proportional...
Abstract. Controlled clinical trials in renal transplantation have demonstrated that mycophenolate mofetil is well tolerated and has lower transplant rejection rates than azathioprine regimens. This study reports on the experiences at two institutions with (MMF) for severe lupus nephritis. Twelve patients relapsing or resistant nephritis previously treated cyclophosphamide therapy one patient who refused as initial diffuse proliferative but accepted MMF were included. During combined...
The aims of this study were to determine the frequency venous thromboembolic events in a large cohort patients with idiopathic membranous nephropathy and identify predisposing risk factors.We studied biopsy-proven from Glomerular Disease Collaborative Network (n=412) Toronto Glomerulonephritis Registry (n=486) inception cohorts. cohorts pooled after establishing similar baseline characteristics (total n=898). Clinically apparent radiologically confirmed identified. Potential factors...
Background and objectives In ANCA-associated GN, severe renal dysfunction portends a poor prognosis for recovery patient survival. This study evaluated the prognostic factors affecting outcomes in patients presenting with kidney failure to guide immunosuppressive therapy. Design, setting, participants, & measurements retrospectively clinical histopathologic characteristics of 155 who underwent biopsy between October 1985 February 2011 (median eGFR at presentation, 7.1 ml/min per 1.73 m2; 87%...
The optimal course of glucocorticoid therapy in anti-neutrophil cytoplasmic autoantibody (ANCA) disease is unknown. This cohort study evaluates effects duration on patient outcomes and adverse events.This assessed 147 patients diagnosed between January 1, 2000 2009 who were treated with glucocorticoids cyclophosphamide. Patients end stage kidney at presentation, treatment resistance, or had died within 6 months excluded. divided into three groups: 0, 5, >5 mg prednisone daily after...
Membranous Nephropathy (MN) is an autoimmune disease associated with antibodies against podocyte proteins: M-type phospholipase A2 receptor (PLA2R1) or thrombospondin type-1 domain-containing 7A (THSD7A) in 70 and 3% of patients, respectively. Antibody titer correlated activity: rising during active decreasing before remission. Therefore, PLA2R1-Antibodies has become important goal therapy. Rituximab a chimeric monoclonal antibody induces remission 60-80% primary MN patients. All such as...
Improvement of proteinuria as a marker for disease activity is associated with better renal outcome in immunoglobulin A nephropathy (IgAN). Complement an effector pathway IgA-mediated kidney injury. Avacopan, selective C5a receptor inhibitor, has previously shown efficacy anti-neutrophil cytoplasmic antibody-associated vasculitis. The aim this study was to evaluate the safety and avacopan patients IgAN persistent despite maximally tolerated dose renin-angiotensin-aldosterone system blockade....
The diagnosis of nephrotic syndrome relies on clinical presentation and descriptive patterns injury kidney biopsies, but not specific to underlying pathobiology. Consequently, there are variable rates progression response therapy within diagnoses. Here, an unbiased transcriptomic-driven approach was used identify molecular pathways which shared by subgroups patients with either minimal change disease (MCD) or focal segmental glomerulosclerosis (FSGS). Kidney tissue transcriptomic...